Multivalent Glycan Ligands for Retinal Outer Segment Assembly
Solution Overview
Problem
Current understanding of molecular signals regulating photoreceptor outer segment assembly in the retina is limited, and there is a need for better therapeutic approaches to address retinal diseases and disorders involving photoreceptor integrity.
Innovation Solution
A novel glycan-binding protein associated with photoreceptor outer segment assembly has been discovered, and multivalent N-linked oligosaccharides with specific structures are used to bind with high affinity to this receptor, promoting OS membrane assembly and integrity, which are administered as pharmaceutical compositions for treating retinal diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monovalent ligands are used to bind to glycan-binding proteins, then the binding affinity is insufficient, but using multivalent ligands increases complexity of the therapeutic composition
Solution Approach 1:
The multivalent ligand is divided into multiple identical or similar glycan units (segments) that are repetitively arranged. Each glycan unit independently binds to glycan-binding proteins, and the cumulative effect of multiple binding sites creates high overall affinity without requiring complex heterogeneous structures
Solution Approach 2:
The patent uses replicated copies of the same glycan motif (e.g., multiple copies of Gal-GlcNAc disaccharide units) arranged in a multivalent structure. These identical copies work together to achieve high binding affinity through cooperative binding, simplifying the design while maximizing therapeutic effect
2Reliability
If more research is conducted to understand molecular signals regulating photoreceptor outer segment assembly, then therapeutic efficacy improves, but development time and cost increase
Solution Approach 1:
The patent performs preliminary identification and characterization of the glycan-binding protein target and its specific glycan ligands before developing full therapeutic formulations. This preliminary research establishes the molecular mechanism and validates the target, enabling faster progression to clinical development with reduced uncertainty
Solution Approach 2:
The patent uses multivalent glycan ligands as intermediaries that bridge the gap between basic research findings and therapeutic application. These ligands serve as proof-of-concept molecules that validate the therapeutic mechanism while being relatively simple to produce and test, accelerating the translation from molecular discovery to clinical therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of multivalent glycan-binding proteins and oligosaccharides supports photoreceptor OS assembly and integrity, offering a therapeutic approach for various retinal diseases, including age-related macular degeneration and retinitis pigmentosa, by promoting membrane formation and adherens junction integrity.
Implementation Method 1
multivalent N-linked oligosaccharides with specific structures are used to bind with high affinity to this receptor, promoting OS membrane assembly and integrity
Data Source
AI summary
Disclosed are novel methods of treatment for retinal diseases and conditions including age-related macular degeneration, genetic-based retinal degenerations and retinal detachment. A novel glycan binding protein thought to be a cell surface receptor has been discovered in the retina. The retinal glycan binding receptor is shown to play an important role in promoting assembly of outer segment (OS) membranes by the photoreceptor cells of the eye, a process that is essential for vision. Based on the finding that certain sugars can bind with very high affinity to the retinal glycan receptor and stimulate its function, the invention provides novel therapeutic agents for treatment of retinal diseases that are multivalent N-linked glycans. Preferred pharmaceutical compositions in accordance with the present invention comprise active agents having the general formula: (Gal-GlcNAc)n-Man3-GlcNAc2, where n is 1-4. Particularly preferred multivalent glycans are galactosylated, biantennary (NA2), and asialo, galactosylated, triantennary (NA3) oligosaccharides.



